Weight loss : In a phase 2 clinical trial , adults with overweight or obesity lost an average of 9.4%14.7% of their starting weight after 36 weeks of taking orforglipron
Differences between GLP-1R agonists GLP-1R agonists already in the market and others in development present the same mode of action and, having the same pleiotropic effects of native GLP-1, the differences in clinical profiles between them are related to differences in pharmacokinetics, structure and size of each formulation
If you want to learn how to get insights like these delivered to your inbox every day, and get access to our data-driven forecasts, reports, and industry benchmarks, schedule a demo with our sales team
cAMP is a major second messenger in the heart where it controls diverse physiological functions such as Ca 2+ homeostasis, myocardial contractility, and cell death as well as regulation of mitochondrial function ( 2 O 2 -induced intracellular ROS production via Epac-dependent pathway and suppressed H 2 O 2 -induced apoptosis through both PKA- and Epac-dependent signaling pathways in rat cardiac myocytes ( A possible role of Epac in regulating mitochondrial functions has been described and might be reflected by types and localization of Epac proteins in mitochondria ( Activation of PKA inhibits Akt phosphorylation in cortical neurons, whereas activation of Epac induces Akt phosphorylation mediated through Rap activation emphasizing cAMP/Epac/Akt signaling pathway ( Figure 5 ), suggesting that both PI3K and Akt serve as downstream effectors of Epac-mediated GLP-1R signaling in the heart
